Clinical Trials Logo

Filter by:
NCT ID: NCT05822453 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma

Start date: April 30, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of 1st line therapy with gemcitabine plus S1 and tislelizumab in participants with advanced biliary tract carcinoma (BTC).

NCT ID: NCT05822284 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

Start date: April 2023
Phase:
Study type: Observational

The goal of this observational study is to explore whether ctDNA-MRD dynamic monitoring can more effectively predict the therapeutic effect of induction chemoimmunotherapy followed by surgery or non-surgical treatment for stage IIIB-C driver-negative NSCLC in the MDT model, so as to accurately guide clinical diagnosis and treatment.

NCT ID: NCT05821452 Not yet recruiting - Chemotherapy Clinical Trials

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Start date: May 25, 2023
Phase: Phase 2
Study type: Interventional

The investigators conducted a phase II, prospective, two-arm clinical study to explore the efficacy of Camrelizumab combined with chemotherapy versus chemoradiotherapy for conversion therapy of potentially resectable advanced esophageal squamous cell carcinoma. This study will provide more evidence for conversion treatment of initially unresectable locally advanced esophageal squamous cell carcinoma and contribute to the development of treatment guidelines for esophageal cancer.

NCT ID: NCT05821361 Not yet recruiting - Clinical trials for Unrescetable Hepatocellular Carcinoma

HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of HAIC combined with Cadonilimab and bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma

NCT ID: NCT05819060 Not yet recruiting - Clinical trials for Recurrent Ovarian Cancer

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

Start date: April 30, 2023
Phase: Phase 2
Study type: Interventional

The study will be a Prospective, Single-arm, Phase Ⅱ Clinical Study. This study intends to explore the efficacy and safety of Fuzuloparib combined with bevacizumab in the maintenance treatment of patients with platinum-sensitive ovarian cancer. The progression-free survival, OS, and safety were evaluated based on RECIST V1.1.

NCT ID: NCT05817981 Not yet recruiting - Clinical trials for Sexual and Reproductive Health

The Investigation of Knowledge and Educational Demand of Sexual and Reproductive Health Among Cancer Survivors

Start date: May 2023
Phase:
Study type: Observational

The goal of this observational study is to explore the current situation and needs of adolescent and young adult cancer survivors for cancer-related reproductive health and fertility information. The main questions it aims to answer are: 1. What is the status of sexual and reproductive health knowledge among adolescent and young adult cancer survivors? 2. What is the difference between the educational currently available and needs of cancer survivors? Part of the participants will be interviewed and then others will fill out questionnaires.

NCT ID: NCT05817864 Not yet recruiting - Capnography Clinical Trials

Diagnostic Accuracy of Capnography in Nasogastric Tube Placement

Start date: June 2023
Phase:
Study type: Observational

A prospective observational diagnostic study will be conducted to assess the sensitivity and specificity of using capnography in detecting the correct placement of nasogastric tubes using the reference standards of radiography and measurement of aspirates for pH value.

NCT ID: NCT05816694 Not yet recruiting - Clinical trials for Histological or Cytological Confirmed Stage ? and ?a Thymoma

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Start date: April 30, 2023
Phase: Phase 2
Study type: Interventional

This study for a single-center prospective phase II randomized controlled train to assess the efficacy and safety of Induction therapy on thymoma .Methods patients with thymoma (stage Ⅲ and stage Ⅳa) were treated with 2 cycles of (NAB)-paclitaxel plus Cisolation (Paclitaxel For Injection(Aalbumin Bound)125 mg/m2 Day 1 、Day8 ,Cisplatin 75 mg/m2 Day 1of each 3-week cycle)or CEP(cisplatin 50 mg/m2 Day 1, epirubicin 75 mg/m2 Day 1,cyclophosphamide 500 mg/m2 Day 1 of each 3-week cycle). Following chemotherapy to evaluate the patient for operation. Patients without undergo surgery will be continued to receive 2 cycles of Primary chemotherap.

NCT ID: NCT05814731 Not yet recruiting - Conditioning Clinical Trials

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

According to the 2022 ELN guidelines patients with high-risk acute myeloid leukemia were randomly divided into MA-BUCY2 conditioning group and BuCy2 conditioning group,to evaluate the efficacy and safety of two conditioning regimens in haploidentical hematopoietic stem cell transplantation.

NCT ID: NCT05814718 Not yet recruiting - Conditioning Clinical Trials

Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

A multicenter randomized study on the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with carmustine, etoposide, and cytarabine (modified BEAM protocol) in the pretreatment of T-cell lymphoma underwent autologous stem cell transplantation